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Abstract 
Development of the pharmacology of Acid-Sensing Ion Channels (ASICs) has become 
a key challenge to study their structure, their molecular and cellular functions and their 
physiopathological roles. This review provides a summary of the different compounds that 
directly interact with these channels, either with inhibitory or stimulatory effect, and with high 
selectivity or poor specificity. They include drugs and endogenous regulators, natural 
compounds of vegetal origin, and peptides isolated from animal venoms. The in vivo use of 
some of these pharmacological modulators in animal models and a few small clinical studies 
in humans have provided substantial data on the physiological and physiopathological roles of 
ASIC channels. Modulation of these channels will certainly provides new therapeutic 
opportunities in neurological and psychiatric diseases including pain, stroke, epilepsy, 
anxiety, depression or traumatic injury, as well as in some non-neurological pathologies. 
 
Introduction 
ASIC channels are voltage-insensitive, proton-gated cation channels activated by 
extracellular acidosis (Waldmann et al., 1997b). They belong to the ENaC (Epithelial Na
+
 
Channel)/DEG (Degenerin)/ASIC (Acid-sensing ion channel) superfamily of ion channels, 
which share the same topology of their subunits (two transmembrane domains, a large 
extracellular loop, and short intracellular N and C- termini), and form amiloride-sensitive 
cation channels. In rodents, four genes encode at least six different ASIC subunits, ASIC1a, 
ASIC1b, ASIC2a, ASIC2b, ASIC3, and ASIC4. These subunits are highly expressed in 
neurons, but also in several non-neuronal tissues. ASIC1a and ASIC2 (both variants a and b) 
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are primarily expressed in the central nervous system, while almost all subunits (except 
ASIC4) are expressed in sensory neurons of the peripheral nervous system(Noël et al., 2010). 
Crystallization by the group of Eric Gouaux of the ASIC1a channel from chicken 
(Jasti et al., 2007) has shown that three subunits are required to form a functional channel that 
can be either homo- or heteromeric. Interestingly, it has been shown recently that the 
recombinant ASIC1a and ASIC2a subunits can assemble with a flexible stochiometry, i.e., no 
preference for homo- or heteromeric combination of subunits (Bartoi et al., 2014). ASIC2b 
and ASIC4 are not forming functional proton-gated channels on their own but can contribute 
to heteromeric channels with other ASIC subunits to modulate, at least for ASIC2b, the 
properties and the regulation of the channels (Noël et al., 2010). Based on the chicken 
ASIC1a structure, a model has been proposed where each subunit is represented as a hand 
holding a ball and divided into finger, thumb, palm, knuckle, β-ball, wrist, and forearm as the 
transmembrane domains TM1 and TM2. An “acidic pocket” containing several pairs of acidic 
amino acids is present at the interface between two subunits and has been proposed to be one 
of the pH-sensor of ASIC channels, whereas cations may access the ion channel by lateral 
fenestrations in the wrist region, then moving into a broad extracellular vestibule (Gonzales et 
al., 2009; Jasti et al., 2007) (Fig. 1).  
The pharmacology of ASIC channels is diverse and has significantly increased in 
recent years, including synthetic compounds (Table 1), endogenous regulators (Table 2), 
natural products from plants and animals (Table 3), either with inhibitory or stimulatory effect 
and of high or poor selectivity. 
 
1-Pharmacology 
1.1-Synthetic compounds 
1.1.1-Amiloride and its derivatives  
Amiloride, a K
+
-sparing diuretic currently licensed for hypertension and heart failure, 
was the first blocker of ASIC channels to be described (Waldmann et al., 1997a; Waldmann et 
al., 1997b; Waldmann et al., 1996). Amiloride acts as a non-discriminative low affinity pore-
blocker of ASIC channels (IC50 between 5 and 100 μM), but also blocks other ionic channels 
and exchangers (Frelin et al., 1988; Kleyman and Cragoe, 1988). Interestingly, the sustained-
component of the ASIC3 current is resistant to amiloride blockade. The amiloride derivatives 
benzamil and EIPA are also low affinity, poorly selective, reversible blockers of ASIC 
channels. Structure-function studies have identified amino acids possibly implicated in the 
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amiloride block and located in the second transmembrane domain on the extracellular side of 
the channel gate (Kellenberger et al., 2003; Schild et al., 1997). Co-crystallization of the 
chicken ASIC1a channel in the presence of amiloride confirmed that amiloride partially 
occlude the pore in the extracellular vestibule (Baconguis et al., 2014), probably blocking ion 
conduction by dipping the amidino group into the pore (Fig. 1). In addition to its blocking 
effect, amiloride has an additional paradoxical enhancing effect at high concentrations, and is 
able to open homomeric ASIC3 channels (EC50 of 560 µM) and heteromeric ASIC3+ASIC1b 
channels at neutral pH, and also to synergistically enhance the channel activation driven by 
mild acidosis (Adams et al., 1999; Li et al., 2011; Waldmann et al., 1997a; Yagi et al., 2006). 
This activating effect, contrary to the inhibitory effect, has been shown to be dependent on the 
integrity of a non-proton ligand sensing domain present in ASIC3 channel (Li et al., 2011). 
However, two molecules of amiloride were found within the acidic pocket of ASIC1a after 
co-crystallization of the drug with the channel, suggesting the possibility that binding of 
amiloride to the acidic pocket could also be involved in its paradoxical activating effect 
(Baconguis et al., 2014; Yu et al., 2011) (Fig. 1). 
 
1.1.2-GMQ 
A set of small molecules inspired from amiloride and containing a guanidinium group 
and a heterocyclic ring, has been also shown to activate/modulate ASIC3 channels (Yu et al., 
2010), among which the synthetic GMQ (2-guanidine-4-methylquinazoline, EC50 ∼ 1 mM,). 
GMQ is able to generate a current at neutral pH that displays little or no desensitization. The 
binding site of GMQ is distinct from the site involved in pH-sensing (Yu et al., 2010; Yu et 
al., 2011) (Fig. 1) and GMQ induces an acidic shift of the pH dependence of inactivation of 
ASIC1a, ASIC1b, ASIC2a, and ASIC3 channels. It also affects the pH dependence of 
activation of ASIC3 channels (alkaline shift) and of ASIC1a and ASIC1b channels (acidic 
shift). As a consequence, GMQ creates a window current at pH 7.4 in ASIC3, but is not able 
to activate the other channel subtypes (Alijevic and Kellenberger, 2012). The ASIC3 channel 
activation was shown to be regulated by a dynamic interplay between GMQ and extracellular 
protons and Ca
2 
(Yu et al., 2010). Recently GMQ was also shown to inhibit GABAA ligand-
gated channels with an IC50 of 0.4 µM (Xiao et al., 2013). 
 
1.1.3-A-317567  
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A-317567 is a small molecule unrelated to amiloride, which has been described to be 
more selective than amiloride for ASIC channels, but remains a non-discriminative inhibitor 
of ASIC currents (IC50 : 2-30 μM) in sensory and central neurons (Coryell et al., 2009; Dube 
et al., 2005). The amidine moiety of A-317567 is critical for the inhibitory effect on ASIC3 
current. A more potent analog was created that inhibits recombinant human ASIC3 and 
ASIC1a currents with a better potency (IC50 ∼ 356 and 450 nM, respectively) (Kuduk et al., 
2010). Unlike amiloride, A-317567 blocks both the fast and sustained phases of the ASIC3 
current with equal potency. However, this compound also interacts (IC50<10 μM) with a 
number of neurotransmitter receptors, suggesting possible off-target effects if used in vivo 
(Kuduk et al., 2010).  
 
1.1.4-Non-steroid anti-inflammatory drugs 
Besides their well-known ability to inhibit cyclooxygeneases, Non-steroid anti-
inflammatory drugs (NSAIDs) also directly inhibit the activity of both ASIC1a and ASIC3 
channels (Voilley et al., 2001)}(Voilley, 2004). Whereas ASIC1a is inhibited by flurbiprofen 
and ibuprofen (IC50 ∼ 350 µM), the sustained current of ASIC3 is blocked by salicylic acid, 
aspirin and diclofenac (IC50: 90-260 µM). ASIC2a has been also shown to be partially 
blocked by 500 µM of diclofenac, as well as heteromeric ASIC1a+ASIC2a currents. A 
proposed mechanism of action is allosteric inhibition of ASIC channels by slowing down the 
recovery after inactivation. No competition between amiloride and diclofenac was found 
(Dorofeeva et al., 2008). NSAIDs were shown to inhibit ASIC currents in cultured brain 
neurons, thus reducing acidosis-induced membrane depolarization (Wang et al., 2012), which 
may indicate that central ASIC channels could be targeted by high doses of aspirin and 
salicylate in the therapeutic concentration range. 
Recently, CHF5074, a NSAID derivative devoided of cyclooxygenase inhibitory 
activity but holding disease-modifying potential for the treatment of Alzheimer’s disease, was 
shown to inhibit low pH-evoked ASIC currents in hippocampal pyramidal neurons (IC50 ∼ 50 
nM). Molecular docking simulations suggest a possible binding site in the -ball region of 
ASIC1a (Mango et al., 2014) (Fig. 1). 
 
1.1.5-Tetraethylammonium and 4-aminopyridine  
ASIC1a+ASIC2(a/b) heteromeric channels are blocked by low millimolar 
concentrations of tetraethylammonium (TEA), a classic nonspecific inhibitor of voltage-gated 
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K
+
 channels (Kv), while homomeric ASIC1a channels are not, providing therefore a 
pharmacological way to differentiate heteromeric ASIC1a+ASIC2b and homomeric ASIC1a 
channels, which have otherwise very similar biophysical properties (Sherwood et al., 2011). 
4-aminopyridine (4-AP), another blocker of Kv channels, strongly inhibits 
recombinant as well as neuronal ASIC1a channels (IC50 ∼ 760 µM) and recombinant 
channels containing the ASIC1a, ASIC1b and ASIC2a subunits, but is less active on ASIC3-
containing channels (no effect on homomeric ASIC3 channels). 4-AP may block ASICs and 
other ENaC/DEG channels through binding into the pore, as for Kv channels (Boiko et al., 
2013) (Fig. 1). 
 
1.1.6-Local Anesthetics 
Local anesthetics have multiple effects including analgesia, which is largely supported 
by inhibition of voltage-gated Na
+
 channels. Some local anesthetics have been shown to also 
inhibit ASIC channels.  
Tetracaine inhibits the peak current of ASIC3 with an IC50 of 10 mM, and also 
partially affects the sustained current. It also blocks the ASIC1b current, but has no effect on 
the ASIC2a current. In cultured mouse sensory neurons, tetracaine inhibits both the peak and 
the sustained ASIC currents (Leng et al., 2013). 
High concentrations of lidocaine also inhibit ASIC currents in mouse cortical neurons 
(IC50 ∼ 12mM) as well as recombinant ASIC1a, but not ASIC2a channels (Lin et al., 2011).  
Propofol was recently shown to partially inhibit recombinant ASIC1a and ASIC3 
currents as well as native ASIC currents in DRG neurons, leading to a decrease of acid-
induced neuronal excitability (Lei et al., 2014). 
 
1.1.7-Others drugs  
A few other non-specific small molecule inhibitors of ASIC channels have been 
described, some being already used in human.  
Benzothiophene methyl amine is a potent, non-amidine ASIC1a and ASIC3 inhibitor 
(IC50 ∼ 220 nM), which also binds to a number of other targets (Kuduk et al., 2011).  
Streptomycin and neomycin, two clinically used aminoglycosides, were shown to 
partially inhibit ASIC currents in DRG neurons (IC50 ~ 32-44 M) (Garza et al., 2010) and to 
reduce acid-triggered action potential discharges (Mercado et al., 2014).  
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The protease inhibitor nafamostat mesilate, used as anticoagulant and against 
pancreatitis, reversibly blocks recombinant human ASIC1a, ASIC2a and ASIC3 channels 
(IC50 ~ 2-70 M) (Ugawa et al., 2007).  
Chloroquine, a widely used anti-malaria drug, has been shown to impair visual 
transduction by inhibition of ASIC1a channels, which are functionally expressed in the retina 
where they are involved in its normal activity (Ettaiche et al., 2006). Chloroquine (IC50 ∼ 600 
µM) reduces the peak amplitude and slows down the inactivation rate of the recombinant 
ASIC1a current and native retinal ganglion neuron currents (Li et al., 2014a).  
Finally, a class of anti-parasitic drugs, the diarylamidines (DAPI, diminazene, 
hydroxystibamidine and pentamidine), which are widely used against trypanosomiasis and 
leishmaniasis, have been shown to potently inhibit ASIC currents in hippocampal neurons 
(IC50 ~ 300 nM – 38 μM), as well as recombinant ASIC1a, ASIC1b, ASIC2a and ASIC3 
channels (Chen et al., 2010).  
Computational docking simulation of nafamostat and diarylamidines to the ASIC1a 
channel suggests that all these dicationic compounds, unlike amiloride, are probably not pore 
blockers but likely bind in a groove-shaped region formed by the β-ball and the palm domain, 
a region that partly overlaps with the binding site of the toxin PcTx1 (Chen et al., 2010) (Fig. 
1). 
 
1.2-Endogenous modulators 
1.2.1-Extracellular cations  
ASICs are inhibited by a variety of heavy metal ions (Gd
3+
, Pb
2+
, Ni
2+
, Cd
2+
, Cu
2+
) 
(Allen and Attwell, 2002; Babinski et al., 2000; Sherwood et al., 2011; Staruschenko et al., 
2007; Wang et al., 2006; Wang et al., 2007) and are also sensitive to bivalent cations (Ca
2+
, 
Mg
2+
, and Zn
2+
) (Baron et al., 2001; Chu et al., 2004; de Weille and Bassilana, 2001; Jiang et 
al., 2010; Poirot et al., 2006; Waldmann et al., 1997b). 
Both the ASIC1a and ASIC2a single-channel conductances are reduced by elevated 
levels of extracellular Ca
2+
 (de Weille and Bassilana, 2001). Extracellular Ca
2+
 modulates the 
apparent H
+
 affinity for ASIC1 and the acidic pocket in the closed state of the channel may 
contain a Ca
2+
 ion that could be displaced upon acidification (Jasti et al., 2007; Paukert et al., 
2008) (Fig. 1). Ca
2+
 ions have also been shown to bind to a high-affinity site on the 
extracellular side of the ASIC3 pore to block permeation of the channel (Immke and 
McCleskey, 2001b, 2003). The site has also been identified in ASIC1a channel, at the 
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beginning of the second transmembrane domain, and Ca
2+
 inhibits the channel in the open 
state (IC50 = 3.9 mM at pH 5.5) with a better affinity than for ASIC1b (IC50 ∼ 10 mM at pH 
4.7) (Paukert et al., 2004). As Ca
2+
 reduce the apparent affinity for amiloride, this supports a 
competition between Ca
2+
 and amiloride at the entrance of the ion pore (Paukert et al., 2004). 
The effect of Mg
2+
 on ASIC channels is comparable to that of Ca
2+
 (Immke and McCleskey, 
2003) (Babini et al., 2002). Cu
2+
, the third most abundant trace element in human body, 
inhibits ASIC currents in central neurons with an IC50 in the µM range (Wang et al., 2007), 
and the neurotoxic metal ion Pb
2+
 strongly blocks ASIC1a-containing channels (IC50 = 5µM) 
(Wang et al., 2006). 
Interestingly, extracellular Zn
2+
 has a dual effect on ASIC channels when coapplied 
with acidic pH : a potentiating effect at micromolar concentrations (EC50 ∼ 120 μM) on 
ASIC2a-containing channels (Baron et al., 2001), and an inhibitory effect at nanomolar 
concentrations (IC50 ∼ 10nM) on both homomeric ASIC1a and heteromeric ASIC1a+ASIC2a 
channels (Chu et al., 2004). High concentration of Zn
2+
 (IC50 ∼ 61 μM) has also been reported 
to inhibit ASIC3 currents (Jiang et al., 2010; Poirot et al., 2006). Homomeric ASIC1b current 
is not inhibited by a co-application of zinc with acidic solution but is suppressed by pre-
applied zinc (at pH 7.4) with an IC50 of 26 µM (Jiang et al., 2011; Poirot et al., 2006). Zn
2+ 
was shown to potentiate the ASIC currents of rat hippocampal neurons (Baron et al., 2002) 
and of mouse dorsal spinal cord neurons (Baron et al., 2008). Very recently, ASIC excitatory 
post-synaptic currents were recorded for the first time in central neurons, which are triggered by 
synaptic acidification (Du et al., 2014; Kreple et al., 2014). Synaptically released Zn
2+
 could 
therefore target post-synaptic ASIC channels and modulate neuronal excitability or synaptic 
plasticity in the CNS.  
Chelation of extracellular divalent cations by lactic acid produced by anaerobic 
metabolism during cardiac ischemia, muscular exercise or metabolic acidosis, was shown to 
potentiate ASIC current amplitude in response to acidosis (Immke and McCleskey, 2001a, b).  
Interestingly, ammonium ions (NH4
+
) were described to open ASIC1a channels 
independently of changes in proton concentration (Pidoplichko and Dani, 2006). Observation 
that NH4
+
 is able to induce long-lasting currents that can produce prolonged depolarization 
and neuronal firing in mouse mid-brain dopaminergic neurons suggests a possible 
contribution of ammonium-gated ASIC currents to toxicity during disorders associated with 
elevated ammonia. 
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1.2.2-Polyamines  
Synthetic GMQ is an activator/modulator of ASIC3 channels (see paragraph 1.1.2). 
The related endogenous polyamine agmatine and its analog arcaine, an inhibitor of NMDA 
receptors, are also able to activate homomeric ASIC3 channels and heteromeric 
ASIC3+ASIC1b channels (EC50 ∼ 10 mM and 1.2 mM, respectively) through direct 
interaction with the non-proton binding domain (Li et al., 2010; Yu et al., 2010) (Fig. 1). 
These data suggest that natural ligands beyond protons may activate ASIC channels under 
physiological or pathological conditions independently of a drop in pH. Agmatine is an 
arginine metabolite implicated in inflammation and pain signaling, infection and cancer. It is 
not clear whether endogenous polyamines would reach the high levels necessary to activate 
ASIC3 channels, but agmatine is able to cooperate with other inflammatory signals to cause 
pain-related behaviors in an ASIC3-dependent manner (Li et al., 2010), suggesting that much 
lower concentrations could be actually necessary if co-applied with other ASIC3 modulators. 
Furthermore, polyamines are also known to accumulate in synaptic and dense core vesicles, 
raising the possibility that these molecules might also activate ASIC3 during synaptic activity 
(Yu et al., 2010).  
Spermine, a polyvalent cation agonist of NMDA receptors, also increases ASIC1a, 
ASIC1b, and ASIC1a+ASIC2a currents by shifting their pH dependence of inactivation 
(Babini et al., 2002; Duan et al., 2011). It increases ASIC currents in rat hippocampal neurons 
with an EC50 of 495 nM (Duan et al., 2011). The effect of spermine on ASIC channels in the 
central nervous system could be responsible for its neurotoxicity during brain ischemia.  
 
1.2.3-Neuropeptides  
FMRFamide and related peptides are direct activators of the invertebrate FMRFamide-
gated Na
+
 channel (FaNaC) (Lingueglia et al., 1995; Lingueglia et al., 2006) and of Hydra-
RFamide-gated Na
+
 channels (HyNaC) (Durrnagel et al., 2010; Golubovic et al., 2007), two 
members of the ENaC/DEG/ASIC superfamily of ion channels. FMRFamide and RFamide-
related peptides, such as FRRFamide, or their mammalian relatives neuropeptide FF (NPFF, 
FLFQPQRFamide) and neuropeptide SF (NPSF, SLAAPQRFamide), are not direct agonists 
of ASIC channels but potentiate H
+
-gated current of recombinant ASIC1a and ASIC3 
channels (EC50 ~ 10–50 μM) (Askwith et al., 2000; Catarsi et al., 2001; Chen et al., 2006; 
Deval et al., 2003; Sherwood and Askwith, 2008), the effects being more pronounced on 
ASIC3 currents (Lingueglia et al., 2006). FMRFamide and related peptides act directly on the 
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channel (Askwith et al., 2000; Deval et al., 2003) to increase the peak current and/or to slow 
down the inactivation rate, which induces or increases the sustained phase during 
acidification. The positive modulation of ASIC-mediated sustained depolarization by 
RFamide-related peptides could play a role in regulating nociceptor excitability under 
inflammatory conditions (Deval et al., 2003). Regions of the extracellular palm domain and 
the β11-12 linker, belonging to the central vestibule, and important for inactivation and 
steady-state desensitization of ASIC1a have been suggested to be involved in the FRRFamide 
potentiating effect (Frey et al., 2013) (Fig. 1). 
Two endogenous opioid neuropeptides, dynorphin A and big dynorphin, have also 
been shown to directly bind to ASIC1a (EC50 33 and 26 nM, respectively) to enhance channel 
activity by preventing steady-state desensitization. Big dynorphin also enhances ASIC1b 
current. The binding site for dynorphin may overlap with the binding site of the spider toxin 
PcTx1 (Sherwood and Askwith, 2009). 
 
1.2.4-Serotonin  
Serotonin (5-HT), an inflammatory mediator known to enhance pain sensation by 
sensory neurons that also acts as a central neurotransmitter, increases the ASIC3-sustained 
current (EC50 ∼ 41 µM) but not the transient current in homomeric but not heteromeric 
channels. This effect does not involve activation of 5-HT receptors, but depends on the direct 
binding in the non-proton ligand sensing domain of ASIC3 (Wang et al., 2013) (Fig. 1). It 
should be noted that serotonin also acts on ASIC3-containing channels in sensory neurons 
through an indirect intracellular signaling pathway involving protein kinase C (Deval et al., 
2004; Qiu et al., 2012) 
 
1.2.5-Arachidonic acid and lipids 
Arachidonic acid (AA), a major metabolite of membrane phospholipids, was shown to 
potentiate, probably through a direct effect, H
+
-gated ASIC currents in sensory and central 
neurons, as well as the currents associated with recombinant ASIC1a, ASIC2a and ASIC3 
channels (concentration range 1-10 µM) (Allen and Attwell, 2002; Deval et al., 2008; Smith 
et al., 2007). The endogenous cannabinoid anandamide (5 µM), which has the same lipid tail 
than AA, potentiates ASIC1a currents on a similar way (Smith et al., 2007). The potent effect 
of AA on the ASIC3 current essentially results from a shift of the pH dependent activation 
towards less acidic values, which increases the window current at pH values close to 
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physiological pH 7.4 (Deval et al., 2008). AA is thus able to interact with other molecular 
signals produced during inflammation to increase the ASIC3 currents and the associated pain 
(Deval et al., 2008). 
 
1.2.6-Nitric oxide 
Nitric oxyde (NO) is a short-lived, plasma membrane diffusible mediator whose 
release is strongly potentiated by inflammation (Eisenhut and Wallace, 2011). Nitric oxide 
donors potentiate both recombinant ASIC1a, ASIC1b, ASIC2b and ASIC3 currents and rat 
sensory neuron ASIC currents by a direct S-nitrosylation of cysteine residues located in the 
extracellular loop of the channel (Cadiou et al., 2007). In central nervous system, NO was 
shown to promote neuronal death by potentiating ASIC currents during mild and moderate 
acidosis (Jetti et al., 2010), which may for instance occur during ischemia.  
 
1.3-Natural compounds 
1.3.1- Natural compounds of vegetal origin 
Several natural products of vegetal origin have been shown to inhibit the activity of 
ASIC channels. Most of them are products that are used in traditional Chinese medicines, and 
it will be interesting to evaluate to what extent ASIC channels contribute to their therapeutic 
effects in vivo.  
Sevanol, a lignan from armenian thyme (Thymus armeniacus) was identified as an 
inhibitor of both the transient and the sustained current of recombinant human homomeric 
ASIC3 current (IC50 ∼ 300µM), and also inhibits ASIC1a current with a six-fold lower 
affinity (Dubinnyi et al., 2012). 
Chlorogenic acid, formed by the esterification of caffeic and quinic acids, is one of the 
most abundant polyphenols in the human diet and is found ubiquitously in plants, fruits and 
vegetables. In addition to its antioxidant, anti-inflammatory and neuroprotective properties, 
chlorogenic acid has potent analgesic properties explaining the effects of traditional medicinal 
plants in several countries. Chlorogenic acid was shown to inhibit native ASIC currents in rat 
sensory neurons (IC50 ∼ 0.2 µM) and to subsequently reduce acid-induced neuronal 
excitability (Qu et al., 2014).  
Gastrodin is a main bioactive constituent of the traditional herbal Gastrodia elata 
Blume, widely used is Oriental countries for centuries as an analgesic, particularly against 
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migraine and headache. Gastrodin was found to inhibit ASIC current of rat sensory neurons 
(IC50 ∼ 0.2µM) thus reducing acid-induced neuronal excitability (Qiu et al., 2014). 
Paeoniflorin is a monoterpene glycoside extracted from the root of Paeonia lactiflora, 
used in traditional Chinese medicine for more than 1,200 years to alleviate many 
inflammatory diseases and to treat neurodegenerative disorders, especially Parkinson disease. 
Among several other effects, it was shown to inhibit native ASIC1a current expressed by a 
pheochromocytoma (PC12) cell line (IC50 ~ 5µM) (Sun et al., 2011).  
Puerarin is an isoflavone, the major bioactive ingredient isolated from the root of 
Pueraria lobata, also well known in Chinese medicine. It shows a wide spectrum of 
pharmacological properties such as vasodilation, cardioprotection, neuroprotection, 
antioxidant, anticancer, anti-inflammation, analgesia, or promoting bone formation (Zhou et 
al., 2013). It was shown to inhibit ASIC currents (IC50 ∼ 38.4μM), and particularly ASIC1a 
current (IC50 ∼ 9.31μM) in hippocampal neurons, thus preventing cells from acidosis-induced 
death (Gu et al., 2010).  
Another flavonoid, Thalassiolin B, a sulfated flavone glycoside isolated from the sea 
grass Thalassia testudinum, was also shown to inhibit ASIC currents in rat sensory neurons 
(IC50 ∼ 27 μM) (Garateix et al., 2011). 
 
1.3.2-Toxins from animal venoms  
Animal venoms have been a valuable source of specific inhibitors for ASIC channels. 
Four main toxins have been identified from animal venoms of various origins: The spider 
peptide psalmotoxin-1 (PcTx1), the sea anemone peptide APETx2, the three snake peptides 
mambalgins and the snake heterodimeric protein MitTx. They have different, although 
sometimes overlapping, pharmacological profiles on the different ASIC channel subtypes 
(Baron et al., 2013). 
 
1.3.2.1-Psalmotoxin (PcTx1)  
This 40 amino-acid peptide has been isolated as a minor component (less than 1%) of 
the South American tarantula Psalmopoeus cambridgei venom (Escoubas et al., 2000), folded 
according to the inhibitor cystine knot (ICK) motif (Escoubas et al., 2003; Saez et al., 2011). 
At physiological pH 7.4, PcTx1 potently inhibit recombinant rodent H
+
-gated homomeric 
ASIC1a channels (IC50 ~ 1 nM) (Escoubas et al., 2000) as well as heteromeric 
ASIC1a+ASIC2b channels with similar affinity (Sherwood et al., 2011), whereas it promotes 
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opening of ASIC1b channels at physiological pH 7.4 (EC50 ~ 100 nM). PcTx1 has complex 
state-dependent effects on ASIC1a and ASIC1b channels that depend on the pH-dependent 
properties of the channels (which are also different for the same channel between different 
animal species, e.g., rodent, chicken and human) and on the pH at which the toxin is applied. 
This leads to three different macroscopic effects that can be observed with PcTx1: inhibition 
of the H
+
-gated ASIC current, stimulation of the H
+
-gated ASIC current, or activation of the 
ASIC current at physiological pH 7.4 (Baron et al., 2013). PcTx1 effect involves principally a 
stabilization of the inactivated state of ASIC1a channel (Chen et al., 2005). The co-
crystallisation of a chicken ASIC1a-PcTx1 complex has shown binding of PcTx1 into the 
acidic pocked (the pH-sensor) of ASIC1 (Fig.1) (Baconguis and Gouaux, 2012). 
 
1.3.2.2-APETx2 
APETx2 (42 amino acid peptide) is a minor (2%) constituent in the venom of the sea 
anemone Anthopleura elegantissima (Diochot et al., 2004), belonging to the disulfide-rich all-
 structural family with a fold typical of the defensin family of peptides (Chagot et al., 2005). 
APETx2 inhibits homomeric rat and human ASIC3 channels (IC50 ~ 37-63 nM and ~ 175 nM, 
respectively), and several heteromeric ASIC3-containing channels: ASIC3+ASIC2b (IC50 ~ 
117 nM), ASIC3+ASIC1b (IC50 ~ 0.9 µM) and ASIC3+ASIC1a (IC50 ~ 2 µM) (Anangi et al., 
2010; Chagot et al., 2005; Diochot et al., 2004; Jensen et al., 2009). APETx2 rapidly and 
reversibly inhibits the transient ASIC3 peak current and the sustained window current evoked 
at pH 7.0 (Deval et al., 2011), but the toxin does not affect the sustained component evoked at 
pH 5.0 (Diochot et al., 2004). However, APETx2 has been also shown to inhibit the 
recombinant and native Nav1.8 voltage-dependent Na
+
 channel (IC50 of 2.6 μM for native 
channel in rat DRG neurons (Blanchard et al., 2012), 55 nM for recombinant rat channel 
(Peigneur et al., 2012), and 6.6 - 18.7 μM for recombinant human channel (Blanchard et al., 
2012; Peigneur et al., 2012)), as well as Nav1.2 (IC50 ~ 114nM) and Nav1.6 currents 
(Peigneur et al., 2012). This dual activity is not very surprising since other sea anemone 
peptides with the same protein scaffold are potent effectors of voltage-sensitive Na
+
 channels 
(Romey et al., 1976). The binding site of APETx2 on ASIC3 is not known, but a recent 
computer docking simulation suggests two putative sites, the first one within the upper 
“thumb” area and the other one between the “wrist” and the “palm” regions, above the 
transmembrane helices and at the interface between adjacent subunits (Rahman and Smith, 
2014) (Fig. 1).  
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1.3.2.3-MitTx 
MitTx was identified from the venom of the Texas coral snake Micrurus tener tener as 
a -bungarotoxin-like structure with two non covalent subunits, a MitTx-α subunit consisting 
of a 60 amino-acid Kunitz type peptide, and a MitTx-β subunit, which is a 120 amino-acid 
phospholipase A2-like protein (Bohlen et al., 2011). MitTx constitutively activates several 
recombinant rodent homomeric and heteromeric ASIC channels (Bohlen et al., 2011; Bohlen 
and Julius, 2012), particularly homomeric ASIC1a and ASIC1b (EC50 ~ 9 and 23 nM, 
respectively), with a much lower effect on ASIC3 (EC50 ~ 830 nM) and on heteromeric 
ASIC1a+ASIC2a channels. MitTx has only weak effects on ASIC2a current when applied at 
physiological pH 7.4, but strongly potentiates the acid-evoked current by shifting its 
activation curve towards less acidic pH. The effect of MitTx on native ASIC currents in 
sensory trigeminal ganglion neurons seems to mainly depend on ASIC1a-containing channels 
because this effect disappears in neurons from ASIC1a-knockout mice (Bohlen et al., 2011). 
Chicken ASIC1a has been recently co-crystallized with MitTx to unveil the first 
physiologically relevant open structure of these channels and to address the structure of the 
selectivity filter (Baconguis et al., 2014). Each heterodimer of MitTx interacts almost 
exclusively with a single subunit by forming extensive contacts from the ion channel wrist to 
the knuckle and thumb domains (Fig.1). An overlap between the binding sites of PcTx1 and 
of the  subunit of MitTx explains why the binding and biological activities of these two 
toxins are mutually exclusive (Bohlen et al., 2011). This is another nice example of how 
toxins targeting ASICs are important tools not only to decode the physiological roles of these 
channels, but also to decrypt their structural and functional features. 
 
1.3.2.4-Mambalgins 
Mambalgins are three 57 amino-acid peptide toxins that have been identified from the 
venom of the African black mamba Dendroaspis polylepis (mambalgin-1 and mambalgin-2) 
and from the venom of the green Mamba Dendroaspis angusticeps (mambalgin-3) (Baron et 
al., 2013; Diochot et al., 2012). They only differ by one residue each and define a new sub-
family of three-finger toxins. Mambalgin-1, -2 and -3 display the same pharmacological 
properties, inhibiting recombinant homomeric rodent and human ASIC1a channels, 
homomeric rodent ASIC1b channels as well as other heteromeric ASIC1a-containing and 
ASIC1b-containing channels with IC50 ranging from 11 to 252 nM (Baron et al., 2013). Due to 
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the fact that mambalgins inhibit all ASIC channels combinations expressed in central neurons 
(i.e., ASIC1a, ASIC1a+2a and ASIC1a+2b), they were found to drastically inhibit the ASIC 
currents of spinal cord and hippocampal neurons (Baron et al., 2008; Baron et al., 2002; 
Diochot et al., 2012). In rat sensory neurons, mambalgins inhibit about 60% of ASIC currents 
and PcTx1 about 40%, which has been attributed to the additional inhibition by mambalgins 
of ASIC1b-containing channels (Diochot et al., 2012). A synthetic version of mambalgin-1 
potently inhibits ASIC currents recorded from human stem cell-derived sensory neurons 
(Young et al., 2014). Mambalgin-1 acts as a gating-modifier that binds to the closed state of 
the channel and induces a strong shift of the pH-dependent activation of ASIC1a channel 
towards more acidic pH, decreasing its apparent affinity for protons (Diochot et al., 2012). 
The binding site and the inhibitory mechanism of mambalgin-2 on ASIC1a have been 
analyzed recently. The toxin binds into the acidic pocket of ASIC1a, showing significant 
overlap with the binding site of PcTx1 (Salinas et al., 2014; Schroeder et al., 2014). A model 
was proposed where binding of mambalgins to the upper part of the thumb domain exerts 
stimulatory effects but interaction with the palm domain of an adjacent subunit and with the 
-ball domain trap the channel in the closed conformation by precluding the conformational 
changes of the palm and -ball that follows proton activation (Salinas et al., 2014).  
 
1.3.2.5-Other animal toxins 
Several sea anemone toxins have been shown to inhibit ASIC channels besides 
APETx2.  
The pi-AnmTx Ugr 9a-1 (Ugr 9-1) peptide from Urticina grebelnyi inhibits both the 
transient and the sustained current of recombinant human ASIC3 current. It completely blocks 
the transient current with an IC50 of ∼10 µM and partially inhibits the sustained current 
(Osmakov et al., 2013).  
PhcrTx1 from Phymanthus crucifer partially inhibits ASIC currents from sensory 
neurons (IC50 ∼100 nM) but also voltage-gated K
+
 currents in the µM range. It presents an 
ICK scaffold and is the first member of a new structural group of sea anemone toxins 
(Rodriguez et al., 2014).  
Other ASIC-targeting toxins probably exist as suggested by in vivo studies in mice 
showing that pain evokes by the venom of the spider Phoneutria nigriventer can be partially 
blocked by amiloride (Gewehr et al., 2013). 
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2- In vivo effects and therapeutic perspectives of ASIC-targeting compounds 
Many data on the physiological and pathological roles of ASIC channels came from 
pharmacological approaches using ASIC-targeting compounds in vivo in animal models as 
well as in some rare small clinical studies in humans (Fig. 2).  
 
2.1-Cutaneous analgesia 
Poorly specific ASIC blockers like amiloride, benzamil, A-317567 and related 
compounds have shown clear analgesic effects after in vivo local application on cutaneous 
pain in models of inflammatory and postoperative pain in rat (Dube et al., 2005; Kuduk et al., 
2011; Kuduk et al., 2009; Rocha-Gonzalez et al., 2009). Streptomycin and neomycin, which 
partially inhibit ASIC currents in DRG neurons, were also shown to exert local analgesia on 
experimental models of inflammatory pain and GMQ-induced pain in rats (Mercado et al., 
2014). All these data were supporting a role for peripheral ASIC channels in cutaneous pain, 
which has long remained unclear because of mixed phenotypes and/or conflicting results from 
studies of knockout and transgenic mice (Chen et al., 2002; Mogil et al., 2005; Page et al., 
2004; Price et al., 2001; Wemmie et al., 2003; Wemmie et al., 2002), most probably because 
of compensatory mechanisms in these constitutive knockout animals. 
The spider toxin APETx2, which blocks ASIC3-containing channels, has potent 
analgesic effects after local application in rodent cutaneous acidic and inflammatory pain as 
well as in post-operative pain, showing the important role of peripheral ASIC3 in primary 
thermal and mechanical hyperalgesia (Deval et al., 2011; Deval et al., 2008; Karczewski et 
al., 2010). The sea anemone toxin Ugr 9-1, another inhibitor of ASIC3 channels, also reversed 
inflammatory and acid-induced pain after intravenous injection (Osmakov et al., 2013). On 
the other side, pharmacological compounds that stimulate ASIC3-containing channels like 
GMQ (Yu et al., 2010), high concentration of amiloride (Li and Xu, 2011) or co-application 
of 5-HT and acid (Li et al., 2011; Wang et al., 2013) were shown to exert nociceptive effects.  
Local peripheral application of the snake toxin MitTx, a potent activator of ASIC1 
channels, strongly suggested a role for peripheral ASIC1a-containing channels in pain 
(Bohlen et al., 2011), while intraplantar injection of mambalgins, which inhibit ASIC1a- and 
ASIC1b-containing channels, provided the first demonstration of a role of DRG-specific 
ASIC1b-containing channels in pain (Diochot et al., 2012).  
Clinical data support the involvement of ASIC channels in cutaneous acid-induced 
pain and inflammation associated pain in human. A decrease in pH in the skin of human 
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volunteers has been associated with non-adapting pain (Steen et al., 1995) and this cutaneous 
acid-induced pain is blocked by amiloride and/or NSAIDs, with a prominent effect for pH > 
6.0 (Jones et al., 2004; McMahon and Jones, 2004; Ugawa et al., 2002). Furthermore, topical 
application of a NO donor increased acid-evoked pain without affecting heat or mechanical-
evoked pain (Cadiou et al., 2007). The extreme pain evoked by the Texas coral snake’s 
venom in humans has also been attributed to the constitutive activation of human ASIC 
channels by the MitTx present in the venom (Bohlen et al., 2011). Interestingly, human stem 
cell–derived sensory neurons express different ASIC channels containing the ASIC1- and 
ASIC3-subunits that are sensitive to different ASIC-inhibiting toxins (Young et al., 2014). 
Several vegetal extracts used in traditional Chinese medicines have been shown to 
target ASIC channels and have analgesic properties in human. To what extent inhibition of 
ASIC channels are responsible for these effects is still not completely clear but experiments in 
animal models are consistent with a possible contribution of ASIC channels. In mice, sevanol 
significantly reverses inflammatory hyperalgesia and acid-triggered visceral pain (Dubinnyi et 
al., 2012), thus explaining the known analgesic effects of thyme extracts. Chlorogenic acid, 
and Thalassiolin B alleviates inflammatory, neuropathic and visceral pain, as well as 
intraplantar acid-evoked pain in rats (Garateix et al., 2011; Qu et al., 2014). Finally, 
subcutaneous injection of gastrodin relieves chemical and acid-evoked pain in rats, without 
involving peripheral opioid receptors (Qiu et al., 2014).  
 
2.2-Muscular pain 
In a rodent model of non-inflammatory muscular pain induced by repeated acid 
injections into the muscle, non-selective or more specific ASIC blockers like amiloride, A-
317567 or APETx2 prevent the secondary mechanical hyperalgesia (i.e., the increased 
response to noxious stimuli outside the site of injury) (Karczewski et al., 2010; Sluka et al., 
2003; Walder et al., 2010). This suggests that the chronic activation of ASIC channels (and 
particularly ASIC3) in muscle nociceptors is important to trigger the subsequent central 
sensitization contributing to secondary mechanical hyperalgesia. Local application of A-
317567 is also blocking pain in a model of muscle inflammation (Walder et al., 2010). Effect 
of A-317567 in ASIC3 knockout mice in this model also suggests the contribution of 
peripheral ASIC1 channels to the primary hyperalgesia in muscle inflammation. 
Rescue of the ASIC3 expression in primary afferent fibers innervating muscle in 
ASIC3 knockout mice restores the mechanical hyperalgesia of the paw (Sluka et al., 2007), 
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whereas downregulation of ASIC3 in muscular sensory fibers in wilde-type animals prevents 
the development of inflammatory hyperalgesia (Walder et al., 2011). Combining ASIC3 
knockout mice and APETx2, the activation of ASIC3 channels were recently shown to be 
essential for the transition from acute to chronic pain in a mouse model of fibromyalgia 
induce by intramuscular acid injections (Chen et al., 2014). As the local injection of A-
317567 induces a reversal of muscle hyperalgesia even in ASIC3 knockout mice, it suggests 
that ASIC1 at the site of muscle inflammation is also important in the generation of muscle 
inflammation (Walder et al., 2010).  
 
2.2-Spinal and supra-spinal pain processing 
Intrathecal (i.t.) amiloride and benzamil injections display antinociceptive effects in 
the rat spinal nerve ligation model suggesting they may present an alternative 
pharmacological tool in the management of neuropathic pain at the spinal level (Jeong et al., 
2013). In mice, i.t. and intracerebroventricular (i.c.v.) injections of the spider toxin PcTx1, a 
specific inhibitor of ASIC1a channels, induce potent analgesic effects in acute pain as well as 
in inflammatory and neuropathic pain models (Mazzuca et al., 2007) through blockade of 
ASIC1a homomeric channels, and probably ASIC1a+ASIC2b channels (Sherwood et al., 
2011). These analgesic effects involve the release, by a yet unknown mechanism, of 
endogenous Met-enkephalin in the cerebrospinal fluid after inhibition of ASIC1a channels. 
PcTx1 (i.t.) also prevent chronic abdominal pain in a rat model of irritable bowel syndrome 
induced by butyrate (Matricon et al., 2011). Central injections of the snake toxins mambalgins 
in mice also induce potent analgesic effects in acute as well as inflammatory pain (Diochot et 
al., 2012), which are independent of the opioid system, contrary to the effects of PcTx1. 
Participation of the ASIC2a subunit in these effects via heteromeric ASIC1a+ASIC2a 
channels provides the first evidence of the involvement of ASIC2a in pain. Interestingly, 
acute inhibition of spinal and supra-spinal ASIC1a-containing channels by these specific 
toxins reveals a role for these channels in pain processing in the CNS, which was not 
anticipated from ASIC1a-knockout animals that have no major pain phenotype (Wemmie et 
al., 2003; Wemmie et al., 2002), probably because of compensatory mechanisms in these 
constitutive knockout mice. 
 
2.3-Migraine 
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Amiloride (Yan et al., 2011), GMQ and APETx2 (Yan et al., 2013) analgesic effects 
have shown a role of peripheral ASIC3 channels expressed in dural afferents in migraine-
related behaviour. PcTx1-containing venom has been recently shown to block cortical 
spreading depression in rats, a phenomenon associated with migraine with aura in human 
(Holland et al., 2012). Interestingly, in a small clinical study amiloride shows some efficacy 
for the reduction of aura and headache symptoms (Holland et al., 2012). 
 
2.4-Articular and bone pathophysiology 
In a rat model of ostheoarthritis, continuous intra-articular administrations of APETx2 
reduced pain-related behaviour and secondary hyperalgesia by local inhibition of ASIC3-
containing channels expressed in sensory neurons (Izumi et al., 2012). ASIC3 is expressed in 
joint afferent sensory neurons but also in chondrocytes and synoviocytes (Ikeuchi et al., 2009; 
Kolker et al., 2010), and the analgesic effects of APETx2 were shown to be complemented by 
a reduction of cartilage damage caused by inflammation (Izumi et al., 2012). Similar results 
have been obtained with amiloride that protects articular chondrocytes from acid-induced 
apoptosis (Hu et al., 2012), leading to chondroprotection in arthritis rats (Yuan et al., 2010a). 
PcTx1-containing venom also significantly inhibits the increase in intracellular Ca
2+
 and the 
acid-induced death of cultured rat articular chondrocytes (Yuan et al., 2010b), as well as of rat 
endplate chondrocytes of intervertebral discs (Li et al., 2014b), suggesting that the inhibition 
of ASIC1a channels could also protect chondrocytes. Interestingly, an increased expression of 
ASIC proteins was recently described in human degenerated intervertebral discs compared to 
healthy tissues (Cuesta et al., 2014). 
Bone homeostasis is strictly regulated by control of bone resorption by osteoclasts and 
bone formation by osteoblasts, and most adult skeletal diseases, such as osteoporosis, are 
mostly due to excess osteoclastic activity. Previous work has shown that ASIC channels are 
expressed at high levels in human bone cells (Jahr et al., 2005). Extracellular acidosis induces 
osteoclastogenesis through intracellular Ca
2+
 rise, and both PcTx1 and specific siRNA 
significantly inhibit these events leading to bone resorption (Li et al., 2013). Thus, ASIC1a 
channels may play a role in pH sensing in osteoclasts, and appear as potential therapeutic 
targets for the treatment of human diseases caused by excessive activity of osteoclasts, such as 
osteoporosis. 
 
2.5-Neuroprotection  
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ASIC1a channels in the CNS participate to acidotoxicity and neuronal death 
associated with ischemia or traumatic injury (Duan et al., 2011; Xiong et al., 2004), and their 
inhibition have neuroprotective effects. In rodents, the i.c.v. injection of amiloride, PcTx1 or 
PcTx1-containing venom protects against severe focal ischemia by reducing the infarct 
volume by more than 50% (Pignataro et al., 2007; Xiong et al., 2004). An intraperitoneal (i.p.) 
injection of flurbiprofen has a similar effect (Mishra et al., 2010). PcTx1-containing venom 
and amiloride also showed neuroprotective effects in animal models of ischemia produced by 
asphyxia-induced cardiac arrest (Tai and Truong, 2013; Yang et al., 2011). In rat spinal cord, 
i.t. injection of PcTx1-containing venom reduces the lesion volume induced by traumatic 
injury and increases locomotor recovery (Hu et al., 2011). The abundance of the endogenous 
polyamine spermine in the central nervous system and its interaction with ASIC channels 
could also have important consequences for neurotoxicity (Babini et al., 2002). The i.c.v. 
delivery of exogenous spermine before middle cerebral artery occlusion increases infarct 
volume, but this toxicity-promoting effect is significantly reduced in ASIC1a-knockout mice 
(Duan et al., 2011). 
Amiloride showed neuroprotective as well as myeloprotective effects in animal 
models of multiple sclerosis (Friese et al., 2007; Vergo et al., 2011). Interestingly, chronic 
brain lesions of patients with progressive multiple sclerosis show an increased expression of 
ASIC1 in axons, and a recent pilot study showed that orally given amiloride could exert 
neuroprotective effects (Arun et al., 2013).  
ASIC channels are involved in normal retinal activity (Ettaiche et al., 2006; Ettaiche et 
al., 2009; Ettaiche et al., 2004). Ischemic retinal ganglion cell injury plays a role in a variety 
of retinal diseases such as diabetic retinopathy, hypertensive vascular disease and glaucoma. 
PcTx1 reduced ischemia-induced cell death of cultured rat retinal ganglion cells (Tan et al., 
2011), and in vivo amiloride significantly decreased ischemia-induced retinal degeneration in 
rats (Miyake et al., 2013). 
ASIC channel inhibitors are also neuroprotective in animal models of 
neurodegenerative diseases. In a mouse model of Huntington’s disease, depletion of ASIC1a 
or treatment with amiloride or benzamil reduced polyglutamine aggregation (Wong et al., 
2008). Furthermore, both amiloride and PcTx1 are neuroprotective in a mouse model of 
Parkinson’s disease (Arias et al., 2008), and the neuroprotective effect of paeoniflorin, the 
principal active ingredient of an anti-Parkinson's disease traditional Chinese medicine, may 
involve inhibition of ASIC1a channels (Sun et al., 2011). 
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2.6-Psychiatric disorders 
2.6.1-Fear-related behaviours 
In mice, i.c.v. injection of PcTx1-containing venom reduces innate fear-related 
behaviour (Coryell et al., 2007) through inhibition of ASIC1a channels. Accordingly, 
ASIC1a-knockout mice show reduced innate fear, whereas restoring ASIC1a expression in 
the basolateral amygdala of ASIC1a-knockout mice rescues contextual fear conditioning 
(Coryell et al., 2008), and overexpression of ASIC1a in transgenic mice increases fear 
conditioning (Wemmie et al., 2004). Recently, acidification of the synaptic cleft upon 
physiological neuronal activity was found to activate post-synaptic ASIC currents in the 
lateral amygdala, which are blocked by amiloride but not by PcTx1 (Du et al., 2014), and are 
involved in synaptic plasticity processes underlying amygdala-dependent fear-related learning 
and memory. 
Anxiolytic-like effects of PcTx1 have also been described. In the stress-induced 
hyperthermia model, i.c.v. administration of PcTx1-containing venom prevents stress-induced 
elevations in mice core body temperature (Dwyer et al., 2009). GABAergic mechanisms in 
the amygdala were proposed to mediate these anxiolytic-like effects, but the precise pathways 
involved are not known. Recently, a genetic variation of the human gene coding for ASIC1a 
has been associated with panic disorder and with amygdala phenotypes that have been linked 
to proneness to anxiety (Smoller et al., 2014).  
 
2.6.2-Depression 
An i.c.v. injection of PcTx1 has antidepressant effects (Coryell et al., 2009) through 
inhibition of ASIC1a channels. ASIC1a-knockout mice are resistant to depression, whereas 
restoring the expression of ASIC1a in the amygdala of ASIC1a-knockout mice eliminates the 
antidepressant-like phenotype. A-317567, a non-discriminative inhibitor of ASIC channels, 
also exerts antidepressant effects through ASIC1a blocking after i.c.v. injection (Coryell et al., 
2009). These findings raise the possibility that inhibiting ASIC1a channels might reduce 
depression. 
 
2.7-Epilepsy 
In an in vivo model of kainate-induced epilepsy, i.c.v. injection of PcTx1 reduces both 
the seizure activity and the neuronal injury (Xiong et al., 2008), consistent with other studies 
 21 
 
showing an inhibition of seizures by amiloride in rats and mice (Ali et al., 2006; Luszczki et 
al., 2009; N'Gouemo, 2008; Quansah and N'Gouemo, 2014). This raises the possibility of a 
contribution of ASIC channels, and ASIC1a-containing channels in particular, to the 
generation and/or maintenance of seizures. However, other results have shown that i.c.v. 
injection of PcTx1-containing venom, or deletion of ASIC1a, increased seizure severity in 
mice, which has been associated with a protecting role of ASIC1a-containing channels in 
seizure termination by acidosis through an increase in the inhibitory tone of inhibitory 
interneurons (Ziemann et al., 2008). Further studies will certainly provide a better 
understanding of the different contributions of ASIC channels in epilepsy.  
In humans, genetic study suggested an association between single nucleotide 
polymorphisms in ASIC1 and temporal lobe epilepsy (Lv et al., 2011). A down regulation of 
the expression of ASIC1a was also reported in cortical lesions of patients with focal cortical 
dysplasia, a well-recognized cause of medically intractable epilepsy (Guo et al., 2014), which 
suggest that ASIC1a loss may contribute to epileptogenesis in these patients.  
 
2.8-Inhibition of acidosis-induced hyperventilation and bradycardia 
Recent data obtained in rats also support the involvement of ASIC channels in central 
chemoreception and breathing control. Injection of PcTx1 in the lateral hypothalamus inhibits 
ASIC1a channels in orexin neurons and the orexin action on the medulla respiratory centre, 
which blocks the increase in breathing frequency induced by extracellular acidosis (Song et 
al., 2012). ASIC-containing neurons are also present in the nucleus of the solitary tract that 
project to respiratory centres to increase breathing frequency in hypercapnic rats (Huda et al., 
2012). 
Cardiorespiratory homeostasis is regulated by central pH sensitivity. Genetic deletion 
of ASIC2 leads to hypertension and increased heart rate in conscious mice, due to an 
enhanced sympathetic and depressed parasympathetic cardiovascular control (Lu et al., 2009). 
In rats, pretreatment with either amiloride or benzamil abolishes the bradycardia induced by 
microinjection of acidic artificial cerebrospinal fluid (pH 6.2) into the nucleus ambiguus 
(Brailoiu et al., 2014), thus supporting a critical role for ASIC channels in modulating cardiac 
vagal parasympathetic tone and provide a potential mechanism for acidosis-induced 
bradycardia. 
 
2.9-Vascular tone control  
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Amiloride and APETx2 markedly attenuate the exercise pressor reflex generated by 
contracting skeletal muscle (Hayes et al., 2007; McCord et al., 2009; Tsuchimochi et al., 
2011). The role of ASIC channels in the local vascular control is supported by the expression 
of ASIC3 in muscle metaboreceptors, the sensory nerves that innervate muscle arterioles and 
detect changes in muscle metabolism (Molliver et al., 2005). Through inhibition of ASIC3-
containing channels in sensory neurons, APETx2, amiloride and diclofenac inhibit skin 
vasodilation response to direct pressure (pressure-induced vasodilation or PIV) in both 
humans and rodents (Fromy et al., 2012).  
ASIC channels are also expressed in vascular smooth muscle cells from arteries 
(Drummond et al., 2008). In rat pulmonary arteries, PcTx1 reduces store-operated calcium 
entry in vascular smooth muscle cells (Jernigan et al., 2009), as well as agonist-induced 
vasoconstriction, agonist-induced increase in intracellular Ca
2+
 and the hypoxia-induced 
enhanced store-operated calcium entry (Jernigan et al., 2012). These results suggest that 
ASIC1a-containing channels could be involved in the effect of chronic hypoxia on vascular 
tone.  
 
2.10-Adipocytes physiology and diabetes 
ASIC3 current are expressed by adipose cells, and ASIC3-knockout mice show a lean 
phenotype (related to a smaller size of adipocytes), enhanced insulin sensitivity and a 
protection against age-dependent glucose intolerance. The i.p. injection of APETx2 in aged 
wild-type mice produces the same effects (Huang et al., 2008), thus supporting a role for 
ASIC3 in age-dependent glucose intolerance and insulin resistance in adipocytes, which may 
relate to their capacity to sense lactate. Indeed, elevated basal level of lactate is consistently 
found in diabetic subjects who also display marked insulin resistance (DiGirolamo et al., 
1992).  
 
2.11- Hepatic fibrosis 
Liver fibrogenesis is a common widespread pathophysiological response to hepatitis 
viral infections and alcohol toxicity; amplified by a chronic inflammation. In the pathological 
process, protons are released by damaged cells and acidosis plays a critical role in cell injury 
and activation of hepatic stellate cells involved in the fibrotic cascades. Through inhibition of 
ASIC1a channels, PcTx1 was recently showed to inhibit the signs of progression of rat 
hepatic fibrosis (Wu et al., 2014). In vivo experiments showed that amiloride could 
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significantly alleviate rat liver injury, and reduce pathological tissue damage (Pan et al., 
2014).  
 
2.12-Gliomas 
Grade IV gliomas are the most common and most aggressive of all brain tumors, 
exhibiting high rates of proliferation and migration, often setting up secondary foci distant 
from the primary tumor. Glioblastoma cells exhibit constitutively active amiloride- and 
PcTx1-sensitive ASIC currents. PcTx1 and ASIC1-silencing inhibit migration and 
proliferation of cultured human glioma cells. Similarly, the amiloride analogue benzamil 
caused cell cycle arrest (Rooj et al., 2012). These results suggest the intriguing possibility that 
targeting pH and ASICs might inhibit the growth and spread of some cancers. 
 
Conclusion 
Acid-sensing ion channels are directly modulated by a variety of compounds of 
synthetic, endogenous and natural origin. The best know synthetic inhibitor of ASIC channels 
is amiloride, which is not selective but is in clinical use and, as such, can be administered in 
humans. Other amiloride related and unrelated molecules can also block ASIC channels with 
poor channel specificity including A-317567, non-steroid anti-inflammatory drugs (NSAIDs), 
local anesthetics, some voltage-gated K
+
 channel blockers like tetraethylammonium and 4-
aminopyridine, and a few other compounds, some in clinical use (benzothiophene methyl 
amine, streptomycin, neomycin, nafamostat mesilate, chloroquine and diarylamidines). Other 
synthetic molecules like GMQ potentiate, or even activate, ASIC channels. Direct 
endogenous modulators that potentiate the activity of ASIC channels include some 
polyamines like agmatine, arcaine or spermine, neuropeptides like RFamide-related peptides 
and opioid-related dynorphin A and big dynorphin, serotonin, arachidonic acid, and nitric 
oxide. Several extracellular cations inhibit the activity of ASICs, with the exception of Zn
2+
 
that has a dual potentiating and inhibitory effect. Natural compounds of vegetal origin have 
been shown to inhibit the activity of ASIC channels, most of them being used in traditional 
Chinese medicines. The most selective modulators of ASIC channels are coming from animal 
venoms with highly selective toxins that inhibit (PcTx1, APETx2, mambalgins) and 
sometimes activate (MitTx) these channels.  
The in vivo effects of several synthetic and/or natural pharmacological modulators of 
ASIC channels (mostly inhibitors), in combination with knockout or knockdown animals, has 
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been successfully used to decipher the physiological and pathophysiological roles of these 
channels. They emerge from these studies as interesting targets for drug development in a 
variety of neurological and psychiatric disorders including pain, stroke, epilepsy, anxiety, 
depression or traumatic injury. An increasing body of data also suggests possible roles outside 
the nervous system (e.g., in hepatic fibrosis or osteoarthritis). Some already identified ASIC 
inhibitors like the specific peptides discovered in animal venoms, could therefore not only be 
pharmacological tools to explore the function of these channels, but also compounds of 
potential therapeutic value, or may alternatively represent new leads for development of 
therapeutically useful inhibitors of these channels. Interestingly, non-selective inhibitors of 
ASIC channels are actually already used in humans, many of them in traditional Chinese 
medicines, and it will be interesting to evaluate the contribution of ASIC channels to their 
therapeutic effect. A few small scale clinical studies in human using amiloride have also given 
encouraging data for cutaneous pain, migraine and multiple sclerosis (Arun et al., 2013; 
Cadiou et al., 2007; Holland et al., 2012; Jones et al., 2004; Ugawa et al., 2002). Targeting 
endogenous modulators of ASIC channels can also be an alternative strategy as suggested by 
the artificial local modulation of NO in human skin (Cadiou et al., 2007). Stimulatory 
compounds could also be of therapeutical interest, for example in case of epilepsy or drug 
addiction, as suggest by recent data showing that synaptic ASIC1a-containing channels in the 
nucleus accumbens inhibit the plasticity underlying addiction-related behavior in mice 
(Kreple et al., 2014). 
The pharmacology of ASIC channels has made rapid progress the last years, and ASIC 
modulators have been instrumental to study the structure, the properties, the functional 
expression and the physiopathological roles of these channels. New therapeutic opportunities 
in neurological and psychiatric diseases, but also in some non-neurological pathologies, will 
certainly come from the inhibition (but also possibly stimulation) of these important channels. 
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LEGENDS 
Table 1: Synthetic modulators of ASIC channels 
Activating/potentiating and inhibitory effects are indicated in red and blue, 
respectively. See the main text for corresponding references. All: all homomeric ASIC 
channels. 
 
Table 2: Endogenous modulators of ASIC channels 
Activating/potentiating and inhibitory effects are indicated in red and blue, 
respectively. See the main text for corresponding references. All: all homomeric ASIC 
channels. 
 
Table 3: Natural compounds targeting ASIC channels 
Compounds of vegetal origin and toxins from animal venoms are displayed on pink 
and yellow backgrounds, respectively. Activating/potentiating and inhibitory effects are 
indicated in red and blue, respectively. See the main text for corresponding references. All: all 
homomeric ASIC channels.  
 
Figure 1: Sites of interaction of the ASIC-targeting compounds  
Schematic representation of an ASIC channel based on the chicken ASIC1a structure 
according to the model of a hand holding a ball (Jasti et al., 2007). Only two subunits out of 
three are shown for clarity. The inhibitory (-) and stimulatory (+) effects of the different 
compounds are indicated. Psalmotoxin 1 (PcTx1) can inhibit or activate ASIC channels 
depending of the channel subtype and the animal species. Amiloride has different binding 
sites associated with its inhibitory and stimulatory effects. An interrogation mark indicates 
that the binding site has not been formally demonstrated, with sometimes different 
possibilities as for APETx2. Note that the listed compounds are not necessarily targeting the 
same ASIC channel subtypes (see text for details). 
 
Figure 2: In vivo effects of the ASIC-targeting compounds 
The subtypes of ASIC channels involved are shown (- and + represent 
pharmacological inhibition and stimulation, respectively). Effects on homomeric or 
heteromeric channels are not distinguished. See text for details. PIV, pressure-induced 
vasodilation. 
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Table 1 
ASIC-targeting drugs Pharmacological/ 
Therapeutic class 
Effective 
concentration range 
ASIC channels 
involved 
Amiloride Diuretic IC50 ∼ 5-100 µM 
EC50 ∼ 560 µM 
All 
ASIC3, ASIC3+1b 
GMQ 
 
Amiloride-derived EC50 ∼ 1 mM ASIC3 
Flurbiprofen, ibuprofen NSAID IC50 ∼ 350 µM ASIC1a 
Salicylic acid, aspirin, 
diclofenac 
NSAID IC50 ∼ 90-260 µM ASIC3 , ASIC2a 
CHF5074 NSAID-derived IC50 ∼ 50 nM Native channels in 
hippocampal neurons 
Tetraethylammonium (TEA) Cation, Kv channel 
inhibitor 
mM range ASIC1a+2a/2b 
4-aminopyridine (4AP) Kv channel inhibitor IC50 ∼ 760 µM All except ASIC3 
Tetracaine Local anesthetic IC50 ∼ 10 mM ASIC3, ASIC1b 
Lidocaine Local anesthetic IC50 ∼ 12 mM ASIC1a 
Propofol Anesthetic 30-300 µM range ASIC1a, ASIC3 
A-317567 Amidine  IC50 ∼ 2-30 µM ASIC3 
Benzothiophene methyl amine  IC50 ∼ 0.22 µM ASIC3, ASIC1a 
Streptomycin, neomycin Antibiotics, 
aminoglycosides 
IC50 ∼ 32-44 µM Native channels in 
sensory neurons 
Nafamostat mesilate Anticoagulant IC50 ∼ 2-70 µM All 
Diarylamidines Anti-parasitic IC50 ∼ 0.3-38 µM All 
Chloroquine Anti-malaria IC50 ∼ 600 µM ASIC1a 
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Table 2 
Endogenous modulators Pharmacological/ 
Therapeutic class 
Effective 
concentration range 
ASIC channels 
involved 
Agmatine, arcaine Polyamines (GMQ-related) EC50 ∼ 1-10 mM ASIC3, ASIC3+1b 
Spermine Polyamines EC50 ∼ 495 µM ASIC1a, ASIC1b, 
ASIC1a+2a 
Cu
2+
, Pb
2+
, Ni
2+
, Cd
2+
, Gd
3+
 Cations µM to mM range All 
Ca
2+
, Mg
2+
 Cations IC50 ∼ 2-10 mM All 
Zn
2+
 Cations EC50 ∼ 120 µM 
IC50 ∼ 10 nM 
IC50 ∼ 26-61 µM 
ASIC2a-containing 
ASIC1a,ASIC1a+2a 
ASIC1b, ASIC3 
NH4
+
 Cations 1-10 mM range ASIC1a 
FMRFamide and RFamide-
related peptides 
Neuropeptides EC50 ∼ 10-50 µM ASIC3, ASIC1a, 
ASIC1b 
Dynorphins Opioid neuropeptides EC50 ∼ 26-33 nM ASIC1a, ASIC1b 
Serotonine Inflammatory mediator EC50 ∼ 41 µM ASIC3 
Arachidonic acid (AA), 
anandamide 
Inflammatory mediator, 
cannabinoid 
1-10 µM range All 
Nitric oxide (NO donors) Inflammatory/ischemia 
mediator 
Potentiation       
(NO donors: 10-
100µM) 
All 
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Table 3 
Natural 
compounds 
Pharmacological/ 
Therapeutic class 
Effective 
concentration range 
ASIC channels involved 
Sevanol Lignan from thyme IC50 ∼ 0.3-1.8 mM ASIC3, ASIC1a 
Gastrodin Vegetal compound IC50 ∼ 0.2 µM Native channels in sensory 
neurons 
Chlorogenic acid Vegetal polyphenol IC50 ∼ 0.2 µM Native channels in sensory 
neurons 
Thallassiolin B Vegetal flavonoid IC50 ∼ 27 µM Native channels in sensory 
neurons 
Puerarin Vegetal flavonoid IC50  ∼ 9-38 µM Native ASIC and ASIC1a 
currents in hippocampal neurons 
Paeoniflorin Vegetal compound IC50 ∼ 5 µM Native ASIC1a channels of PC12 
cell line 
PcTx1 Spider peptide toxin 
(Psalmopoeus 
cambridgei) 
IC50 ∼ 0.4-4 nM 
100-190 nM range 
ASIC1a, ASIC1a+2b 
ASIC1b, cASIC1 
APETx2 Sea anemone peptide 
toxin (Anthopleura 
elegantissima) 
IC50 ∼ 37 nM - 2 µM ASIC3, ASIC3+1a/b, ASIC3/2b 
MitTx Snake toxin (Micrurus 
tener tener)  
EC50 : 9-830 nM All, but strongest effect on 
ASIC1-containing channels 
Mambalgins Snake peptide toxins 
(Dendroaspis polylepis 
polylepis, Dendroaspis 
angusticeps)  
IC50 ∼ 11-250 nM ASIC1a, ASIC1b, 
ASIC1a+2a/2b, ASIC1a+1b 
Ugr 9-1 Sea anemone peptide 
toxin (Urticina 
grebelnyi) 
IC50 ∼ 1.5-10 µM Human ASIC3 
PhcrTx1 Sea anemone peptide 
toxin (Phymanthus 
crucifer) 
IC50 ∼ 100 nM Native channels in sensory 
neurons 
 
 
